Data / Drug companies / Strides Pharma Science Limited
Strides Pharma Science Limited: 184 products in the FDA NDC directory, labeler code 64380
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Strides Pharma Science Limited (labeler code 64380) lists 184 products in the FDA National Drug Code Directory, covering 67 finished drugs by generic name. By type: 183 prescription drugs, 1 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 1, 2026.
The request: Watch Strides Pharma Science Limited (FDA labeler code 64380): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 64380
- Products in commercial distribution
- 184
- Packages
- 330
- Finished drugs by generic name
- 67
- Prescription products
- 183
- Over the counter products
- 0
- Controlled substance products
- Schedule II 9, Schedule III 4, Schedule IV 3
- Flagged as original packager
- 179 of 179 products that carry the flag
- Started marketing in the last 12 months
- 12
- Earliest marketing start
- September 23, 1997
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 180 | 97.8% |
| Authorized generics (NDA) | 2 | 1.1% |
| Bulk ingredients | 1 | 0.5% |
| Other unapproved drugs | 1 | 0.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 183 | 99.5% |
| Bulk ingredients | 1 | 0.5% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 77 | 41.8% |
| Capsule | 40 | 21.7% |
| Tablet, film coated | 26 | 14.1% |
| Capsule, liquid filled | 7 | 3.8% |
| Powder, for solution | 7 | 3.8% |
| Tablet, orally disintegrating | 4 | 2.2% |
| Tablet, extended release | 4 | 2.2% |
| Powder, for suspension | 4 | 2.2% |
| Suspension | 3 | 1.6% |
| Gel | 2 | 1.1% |
| Tablet, coated | 2 | 1.1% |
| For suspension | 2 | 1.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Mycophenolate mofetil | 64380-899 | Powder, for suspension | Generic drugs (ANDA) | September 1, 2026 |
| Tramadol hydrochloride | 64380-778 | Tablet | Generic drugs (ANDA) | September 1, 2026 |
| Tramadol hydrochloride | 64380-791 | Tablet | Generic drugs (ANDA) | July 27, 2026 |
| Omega-3-acid ethyl esters | 64380-761 | Capsule | Generic drugs (ANDA) | May 29, 2026 |
| Benzonatate | 64380-713 | Capsule | Generic drugs (ANDA) | May 29, 2026 |
| Benzonatate | 64380-712 | Capsule | Generic drugs (ANDA) | May 29, 2026 |
| Doxycycline hyclate | 64380-226 | Tablet | Generic drugs (ANDA) | May 14, 2026 |
| Doxycycline hyclate | 64380-225 | Tablet | Generic drugs (ANDA) | May 14, 2026 |
| Oxybutynin Chloride | 64380-190 | Tablet | Generic drugs (ANDA) | April 10, 2026 |
| Sumatriptan | 64380-740 | Injection, solution | Generic drugs (ANDA) | March 16, 2026 |
| Vancomycin hydrochloride | 64380-730 | Capsule | Generic drugs (ANDA) | January 1, 2026 |
| Vancomycin hydrochloride | 64380-729 | Capsule | Generic drugs (ANDA) | January 1, 2026 |
| Hydrocodone bitartrate and acetaminophen | 64380-442 | Tablet | Generic drugs (ANDA) | September 1, 2025 |
| Hydrocodone bitartrate and acetaminophen | 64380-441 | Tablet | Generic drugs (ANDA) | September 1, 2025 |
| Hydrocodone bitartrate and acetaminophen | 64380-440 | Tablet | Generic drugs (ANDA) | September 1, 2025 |
| Celecoxib | 64380-824 | Capsule | Generic drugs (ANDA) | July 1, 2025 |
| Atomoxetine | 64380-478 | Capsule | Generic drugs (ANDA) | July 1, 2025 |
| Atomoxetine | 64380-477 | Capsule | Generic drugs (ANDA) | July 1, 2025 |
| Atomoxetine | 64380-475 | Capsule | Generic drugs (ANDA) | July 1, 2025 |
| Atomoxetine | 64380-474 | Capsule | Generic drugs (ANDA) | July 1, 2025 |
| Atomoxetine | 64380-473 | Capsule | Generic drugs (ANDA) | July 1, 2025 |
| Atomoxetine | 64380-472 | Capsule | Generic drugs (ANDA) | July 1, 2025 |
| Valganciclovir | 64380-161 | Tablet, film coated | Generic drugs (ANDA) | June 16, 2025 |
| Gabapentin | 64380-728 | Tablet | Generic drugs (ANDA) | June 14, 2025 |
| Gabapentin | 64380-727 | Tablet | Generic drugs (ANDA) | June 14, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.